This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I25 (chronic ischemic heart disease) | Special Copayment Reduction: V192 (Special Copayment Reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Coronary artery disease (CAD), atherosclerotic coronary artery disease, stable angina, chronic coronary syndrome (CCS), coronary artery disease |
| C. Adult onset | Presents mainly after the 40s and is characterized by chronic myocardial ischemia due to coronary atherosclerosis; a broad disease group that includes stable angina, silent myocardial ischemia and long-term management after previous myocardial infarction. |
| 1. History | History of the development of coronary artery disease management from 19th-century descriptions of angina to the modern 2024 ESC guidelines on chronic coronary syndromes |
| 2. Causes | Coronary atherosclerosis is the most common cause; multiple risk factors including dyslipidemia, hypertension, diabetes, smoking, obesity and genetic factors |
| 3. Genetics | Variants at the 9p21.3 locus are the strongest genetic risk factor for coronary artery disease; LDL receptor and PCSK9 gene variants are also important |
| 4. General epidemiology | Leading cause of death worldwide; prevalence about 3–5% in Korean adults, rising sharply at age 65 and over, with onset 10 years earlier in men |
| 5. Pathophysiology | Mechanism of atherosclerotic progression in the order endothelial dysfunction → lipid deposition → plaque formation → luminal narrowing → myocardial ischemia |
| 6. Symptoms | Substernal pressure or tightness provoked by exertion or emotional stress; relief at rest and response to nitroglycerin are characteristic |
| 7. Signs | Physical findings are often nonspecific, but in severe cases an S4 gallop rhythm and a transient mitral regurgitation murmur may be observed during ischemia |
| 8. Screening | Cardiovascular risk score calculation, resting ECG, exercise stress testing and coronary artery calcium score (CACS) are the main screening tools |
| 9. Diagnosis | Coronary CT angiography (CCTA), functional imaging (nuclear medicine, stress echocardiography), invasive coronary angiography and FFR measurement |
| 10. Treatment | Integrated treatment strategy including optimal medical therapy (OMT), revascularization (PCI, CABG), lifestyle modification and cardiac rehabilitation |
| 11. Prognosis | Annual mortality of stable angina about 1–3%; prognosis can improve considerably with optimal medical therapy and risk factor management |
| 12. Prevention | Smoking cessation, exercise, healthy diet, control of lipids, blood pressure and blood glucose, and long-term antiplatelet and statin therapy are the key prevention strategies |
| 13. References | Knuuti J, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes … and 9 other papers |
The history of chronic ischemic heart disease begins with the first clinical description of angina. In 1768 the English physician William Heberden presented to the Royal College of Physicians a peculiar syndrome of chest pressure and discomfort occurring on exertion and relieved at rest, naming it "angina pectoris". He surmised that the symptoms originated from a problem of the heart itself, but at the time could not directly establish a link with the coronary arteries. Around 1800, Edward Jenner found atherosclerotic lesions in the coronary arteries of patients with angina, giving the first pathological description of the link between angina and coronary artery disease.
From the late 19th to the early 20th century, the development of the stethoscope, the introduction of blood pressure measurement and the invention of the electrocardiogram (ECG) (Willem Einthoven, 1903) made noninvasive diagnosis of ischemic heart disease possible. In particular, exercise ECG became a central tool in diagnosing chronic ischemic heart disease, and Master's two-step exercise test (1929) was the starting point of standardized testing.
The development of selective coronary angiography by Mason Sones in the 1960s made anatomical evaluation of chronic ischemic heart disease possible, revolutionizing diagnosis and treatment. Subsequently, coronary artery bypass grafting (CABG) was first performed by René Favaloro in 1967, making surgical revascularization possible, and Andreas Grüntzig's first percutaneous transluminal coronary angioplasty (PTCA) in 1977 opened the era of interventional cardiology. The introduction of stents in 1994 lowered restenosis rates and expanded the use of PCI, and the arrival of drug-eluting stents (DES) in 2002 further improved long-term outcomes.
Since the 2000s, advances in coronary CT angiography (CCTA) have made it possible to evaluate coronary anatomy and plaque characteristics noninvasively. The introduction of functional indices such as fractional flow reserve (FFR) and the instantaneous wave-free ratio (iFR) provided important evidence for assessing severity and deciding on revascularization. The 2019 ESC chronic coronary syndrome (CCS) guidelines expanded the concept of stable angina, adopted the term CCS and emphasized the importance of personalized treatment. The 2024 ESC guidelines introduced the concept of ischemia without obstructive atherosclerosis (INOCA/ANOCA), systematizing the diagnosis and treatment of non-obstructive coronary artery disease.
In Korea, coronary interventions have increased sharply since the 1990s, and more than about 100,000 PCIs are currently performed annually. Korean multicenter studies such as KOCES and KAMIR provide important data on the clinical characteristics and treatment outcomes of coronary artery disease in Koreans. National risk factor management policies through the Comprehensive Plan for the Prevention and Management of Cardiovascular and Cerebrovascular Diseases are contributing to reduced cardiovascular mortality.
The most common and important cause of chronic ischemic heart disease is coronary atherosclerosis. Atherosclerosis is a chronic progressive disease that begins with damage to the vascular endothelium and narrows the coronary lumen through lipid deposition, inflammatory cell infiltration and fibrosis. Myocardial ischemia begins to occur when more than about 70–75% of the luminal area is narrowed.
The main risk factors for atherosclerosis are classified into modifiable factors and non-modifiable factors. Modifiable factors include dyslipidemia (elevated LDL cholesterol, low HDL cholesterol, elevated triglycerides), hypertension (systolic blood pressure >130mmHg), diabetes and insulin resistance, smoking, obesity (especially abdominal obesity), physical inactivity and unhealthy dietary patterns. Non-modifiable factors include older age (men ≥55, women ≥65), male sex, and a family history of premature cardiovascular disease (occurring in a first-degree relative, in men under 55 or women under 65).
Besides the major risk factors, emerging risk factors contribute to coronary artery disease risk. Chronic kidney disease (estimated glomerular filtration rate <60 mL/min/1.73m²), inflammatory diseases (rheumatoid arthritis, lupus, psoriasis), sleep apnea, psychosocial stress, depression, early menopause in premenopausal women, and pregnancy-related complications (hypertension in pregnancy, gestational diabetes) have been identified as independent risk factors.
Non-atherosclerotic causes such as coronary vasospasm, coronary artery anomalies (congenital), coronary microvascular dysfunction (INOCA: Ischemia with Non-Obstructive Coronary Arteries), autoimmune vasculitis (sequelae of Kawasaki disease, periaortitis), coronary artery disease after radiation therapy, and vasospasm and accelerated atherosclerosis due to cocaine abuse can also cause chronic ischemic heart disease.
Research on genetic risk factors for chronic ischemic heart disease has advanced dramatically with recent developments in genome-wide association studies (GWAS). The strongest genetic risk factor is single nucleotide polymorphisms (SNPs) at a locus on chromosome 9, short arm, position 21.3 (9p21.3), adjacent to the CDKN2A and CDKN2B genes. The risk allele at this locus increases coronary artery disease risk by about 25–30% and has been confirmed in both Europeans and East Asians.
LDL receptor (LDLR) gene variants cause familial hypercholesterolemia (FH) and are the most common monogenic cause of premature coronary artery disease. Heterozygous FH occurs in about 1 in 500 people, and without treatment, coronary artery disease develops before age 50 in 50% of men and before age 60 in 30% of women. Gain-of-function mutations in the apolipoprotein B (APOB) and PCSK9 (proprotein convertase subtilisin/kexin type 9) genes also cause FH-like phenotypes.
To date, more than 300 loci associated with coronary artery disease have been identified through GWAS. Major genes include GUCY1A3 and CYP17A1, involved in blood pressure regulation; SORT1, APOE and LPA, involved in lipid metabolism; ADAMT37, involved in platelet function; and PHACTR1 and TCF21, involved in endothelial function. The LPA gene, which determines lipoprotein(a) [Lp(a)] levels, is established as an independent and causal risk factor for coronary artery disease.
A polygenic risk score (PRS) is a tool that integrates hundreds to thousands of SNPs to quantify an individual's genetic risk of coronary artery disease and provides additional predictive power to clinical risk prediction models. Khera et al. (2018) reported in Nature Genetics that individuals in the top 8% of PRS have more than a 3-fold increased risk of coronary artery disease. Clinical use of genetic testing may contribute to early detection and initiation of preventive treatment, but it is not yet established as a universal screening test.
Chronic ischemic heart disease is one of the most important causes of death worldwide. According to WHO data, ischemic heart disease causes about 9 million deaths worldwide each year, accounting for about 16% of all deaths. The prevalence of coronary artery disease rose in high-income countries and has recently tended to stabilize somewhat, but it is increasing rapidly in low- and middle-income countries.
In Korea, according to Health Insurance Review & Assessment Service (HIRA) data, the number of patients with ischemic heart disease is steadily increasing, and as of the early 2020s the prevalence of stable angina is estimated at about 3–5% of the adult population. Prevalence rises sharply in the population aged 65 and over, reaching more than 10%. Koreans tend to develop coronary artery disease at a relatively younger age than Westerners and have a high rate of concomitant diabetes.
Sex differences are also clear. Men develop coronary artery disease about 10 years earlier than women, and at younger ages men have a 3–4 times higher incidence than women. However, in women the incidence rises sharply after menopause as the cardiovascular protective effect of estrogen is lost, and the incidence of coronary artery disease in postmenopausal women becomes similar to that of men of the same age. Coronary artery disease in women often presents with atypical symptoms and more frequently involves microvascular disease, so diagnosis tends to be delayed.
Socioeconomic factors also significantly influence the epidemiology of chronic ischemic heart disease. Low socioeconomic status, educational level and social isolation have been identified as independent cardiovascular risk factors, which are related to unhealthy lifestyles, limited access to medical services and chronic stress. In Korea, the prevalence of coronary artery disease is increasing compared with the past owing to rapid economic growth and the spread of Westernized lifestyles, but mortality is improving thanks to advances in medical services.
The main pathophysiology of chronic ischemic heart disease is the chronic progression of coronary atherosclerosis. The atherosclerotic process begins with vascular endothelial injury. Oxidized LDL cholesterol, mechanical shear stress due to hypertension, tobacco toxins, hyperglycemia, infection and the like cause dysfunction of vascular endothelial cells. Dysfunctional endothelial cells produce less nitric oxide (NO) and show increased expression of adhesion molecules (VCAM-1, ICAM-1) and chemotactic factors (MCP-1).
Through the dysfunctional endothelium, oxidized LDL accumulates in the subintimal layer, and monocytes adhere to the intima, differentiate into macrophages and engulf oxidized LDL to form foam cells. These foam cells aggregate to form early fatty streak lesions, and with the subsequent proliferation and migration of smooth muscle cells and secretion of extracellular matrix, a fibrous plaque forms. The center of the plaque consists of a necrotic lipid core, and the exterior is covered by a fibrous cap.
In chronic stable angina, a fixed luminal stenosis causes a supply shortfall when myocardial oxygen demand increases with exercise or emotional stimuli. Normal coronary arteries have a reserve capacity (coronary flow reserve, CFR) that allows perfusion to increase up to 6-fold, but when severe stenosis is present, CFR is reduced and ischemia occurs when demand increases. When coronary microvascular dysfunction is also present, CFR is reduced further.
Unlike the plaque rupture that causes acute myocardial infarction, a stable plaque has a thick fibrous cap and a small lipid core, so the risk of rupture is low. However, even stable plaques can become unstable through inflammation, infection and hemodynamic stress. When myocardial ischemia persists, cardiomyocyte energy production declines (reduced ATP, lactate accumulation) and membrane electrical instability increases, which in the long term can lead to ventricular dysfunction and ventricular remodeling.
The most characteristic symptom of chronic ischemic heart disease is stable angina pectoris. Typical angina is a pressure, tightness or heaviness in the lower or central sternum that, in adults with risk factors, is provoked in situations that increase myocardial oxygen demand, such as exercise, emotional stress, cold weather or after meals, and is relieved within minutes by rest or sublingual nitroglycerin. Sites of radiation include the inner left upper arm, shoulder, neck, jaw and epigastrium.
Besides typical symptoms, atypical symptoms (atypical angina) are commonly observed. Especially in women, patients with diabetes and older patients, dyspnea, fatigue, indigestion, jaw pain or epigastric discomfort alone may appear as symptoms without chest pain. Patients with diabetes often experience silent myocardial ischemia because of autonomic neuropathy. Silent myocardial ischemia is sometimes found incidentally on exercise stress testing or ECG monitoring.
The severity of angina is classified into grades I–IV according to the Canadian Cardiovascular Society (CCS) classification. CCS grade I is a mild form in which symptoms are provoked only by strenuous exertion, and CCS grade IV is a severe form in which symptoms occur even at rest. Angina grade is used to assess functional status, decide on treatment and monitor treatment response.
When chronic myocardial ischemia persists, heart failure symptoms (dyspnea, orthopnea, leg edema, fatigue) may accompany it. When ventricular dysfunction is marked, exercise intolerance and paroxysmal nocturnal dyspnea appear, and in severe cases heart failure symptoms persist even at rest. In addition, when arrhythmias (atrial fibrillation, ventricular arrhythmias) occur, palpitations, dizziness and syncope may accompany them.
Physical findings in chronic ischemic heart disease are often nonspecific at rest in the absence of anginal attacks. However, some findings help with diagnosis and severity assessment. When hypertension is present, elevated blood pressure is observed. In severe dyslipidemia, arcus corneae and xanthomas — particularly tendinous xanthomas on the backs of the hands or the Achilles tendons — may appear, and xanthelasma may be observed around the eyelids.
Although not specific physical findings of coronary artery disease, signs of widespread atherosclerosis such as a carotid bruit, a pulsatile abdominal aortic mass, absent dorsalis pedis and popliteal pulses, and signs of peripheral arterial disease (skin pallor, cold legs, delayed wound healing) may be observed. These indicate that coronary artery disease may be part of a polyvascular atherosclerotic disease.
When severe left ventricular dysfunction is present, an S3 or S4 gallop rhythm may be heard on auscultation. When there is functional mitral regurgitation due to ischemia of the mitral papillary muscles or ventricular dilatation, a systolic murmur is heard at the apex. With severe heart failure, findings of congestive heart failure appear, such as jugular venous distension, pitting leg edema, hepatomegaly, ascites and basal pulmonary crackles. During ischemic attacks, elevated blood pressure, tachycardia, a transient S4 gallop rhythm and a functional mitral regurgitation murmur characteristically appear and then disappear after ischemia resolves.
Screening for chronic ischemic heart disease begins with cardiovascular risk stratification. The 10-year risk of cardiovascular events is calculated using the Framingham risk score, SCORE2 (Europe), PCE (United States), the ASCVD risk calculator and others. In Korea, a Korean cardiovascular risk calculator (KRS) has been developed. In high-risk groups (risk ≥10–20%), detailed screening with additional tests is needed.
The resting 12-lead ECG is a basic screening test that evaluates evidence of previous myocardial infarction (Q waves, ST-T changes), left ventricular hypertrophy, left bundle branch block, arrhythmias and the like. A normal resting ECG does not exclude coronary artery disease, but abnormal findings support the need for additional testing.
The coronary artery calcium score (CACS) quantifies the amount of coronary calcium as an Agatston score using non-contrast cardiac CT and is very useful for improving risk stratification in intermediate-risk patients. When CACS=0, the risk of cardiovascular events over the next 10 years is very low, and CACS ≥400 corresponds to a high-risk group. It involves radiation exposure and cannot evaluate soft tissue, but it is a highly reproducible and cost-effective screening tool.
The exercise ECG (treadmill test) is a noninvasive functional assessment tool that comprehensively evaluates ST changes, arrhythmias, blood pressure response and symptom provocation during exercise. The standardized Bruce or modified Bruce protocol is used. With a sensitivity of about 68% and specificity of about 77%, it is limited on its own but useful when interpreted together with clinical symptoms.
Coronary CT angiography (CCTA) is now established as the primary noninvasive diagnostic tool for chronic ischemic heart disease. The 2019 ESC CCS guidelines recommend CCTA as the first-line diagnostic test in patients with intermediate pretest probability (PTP). CCTA precisely evaluates the anatomical location and degree of coronary stenosis and can also assess plaque characteristics (calcified vs. non-calcified, vulnerable plaque features). The functional ischemic significance can be further evaluated with CT-FFR (CT fractional flow reserve).
Functional imaging of myocardial ischemia consists of nuclear myocardial perfusion scanning (MPS: SPECT or PET), stress echocardiography and stress cardiac MRI. These tests functionally evaluate the extent and severity of ischemia and are used for prognosis prediction and for judging the need for revascularization. PET myocardial perfusion scanning can quantitatively measure coronary flow reserve (CFR) and is also useful for evaluating microvascular dysfunction.
Invasive coronary angiography (CAG) is the "gold standard" for evaluating coronary anatomy. It is now used mainly for planning revascularization and pre-procedural evaluation rather than as a primary diagnostic tool. Fractional flow reserve (FFR) is the standard method for evaluating the functional significance of intermediate stenoses (40–90% stenosis), and FFR <0.80 is judged to indicate a hemodynamically significant stenosis. Non-hyperemic functional indices such as iFR (instantaneous wave-free ratio) and RFR (resting full-cycle ratio) are also used.
Intracoronary imaging with optical coherence tomography (OCT) and intravascular ultrasound (IVUS) is used to evaluate plaque microstructure and optimize stent implantation during procedures. Cardiac MRI excels at evaluating ventricular function, myocardial viability and extent of fibrosis, and is useful when functional evaluation is needed after CCTA or when other test results are discordant.
Treatment of chronic ischemic heart disease rests on three pillars: optimal medical therapy (OMT), revascularization and lifestyle modification. For every patient, a personalized treatment plan is developed that aims simultaneously at symptom relief and prevention of cardiovascular events.
Antiplatelet therapy is based on aspirin (75–100mg/day) alone, and after PCI dual antiplatelet therapy (DAPT) is maintained for at least 6–12 months. In patients intolerant of aspirin, clopidogrel (75mg/day) is substituted. Statins (high-intensity: atorvastatin 40–80mg, rosuvastatin 20–40mg) are used in all patients with coronary artery disease with a target of LDL cholesterol <55mg/dL (or a ≥50% reduction from baseline). PCSK9 inhibitors are added when the target LDL is not reached despite the maximum statin dose.
ACE inhibitors (or ARBs) are used preferentially in patients with ventricular dysfunction (LVEF <40%), diabetes, hypertension or chronic kidney disease. Beta-blockers are effective in controlling angina symptoms, reducing heart rate and reducing myocardial oxygen demand, and contribute to reducing cardiovascular events in patients after myocardial infarction. Calcium channel blockers and long-acting nitrates (LABA) are used as second-line drugs for controlling angina symptoms or as combination with or alternatives to beta-blockers. Ivabradine, ranolazine and trimetazidine are additional drug options for symptom control.
Revascularization is considered when symptoms persist despite optimal medical therapy, or when high-risk anatomical findings (left main disease, three-vessel disease + ventricular dysfunction) or a large area of ischemia are identified. The choice between PCI and CABG follows a Heart Team decision considering the SYNTAX score, anatomical complexity, comorbidities (diabetes, chronic kidney disease) and patient preference. In diabetic patients with multivessel disease, studies such as FREEDOM have confirmed that CABG has superior long-term outcomes compared with PCI.
The prognosis of chronic ischemic heart disease varies greatly with the treatment method and the degree of risk factor management. In patients with stable angina, annual mortality is reported at about 1–3% and the incidence of nonfatal myocardial infarction at about 1–2%. However, prognosis is markedly poor when there are high-risk features such as severe left ventricular dysfunction (LVEF <35%), left main or three-vessel disease, a large area of ischemia, concomitant diabetes or concomitant chronic kidney disease.
Optimal medical therapy, particularly the combined use of high-intensity statins, antiplatelet agents and renin-angiotensin-aldosterone system blockers, is estimated to reduce cardiovascular events by 30–40%. Revascularization is clearly effective for symptom relief, but compared with optimal medical therapy, its survival benefit is more pronounced in specific patient groups with high-risk anatomical findings. The ISCHEMIA trial (2020) showed no significant difference in major cardiovascular events between invasive treatment (PCI/CABG) and optimal medical therapy in patients with stable CAD and moderate to severe ischemia, but the invasive treatment group was superior in symptom control.
Participation in cardiac rehabilitation programs contributes to improved exercise tolerance, enhanced psychological well-being, fewer readmissions and lower mortality, and is recommended for all patients with stable CAD. Prognosis becomes markedly poor when the disease progresses to heart failure, and when LVEF is <35% and symptoms persist despite optimal medical therapy, an ICD (implantable cardioverter-defibrillator) and, if needed, CRT (cardiac resynchronization therapy) are considered.
Prevention of chronic ischemic heart disease is divided into primary prevention (prevention before disease occurs) and secondary prevention (prevention of recurrence after occurrence). The core of primary prevention is early detection and active management of cardiovascular risk factors. Smoking cessation is the most effective single preventive measure, reducing coronary artery disease risk by more than 50%. The risk falls markedly within 1–2 years of quitting and approaches the level of nonsmokers within 10 years.
Blood pressure control targets systolic blood pressure <130mmHg (diabetes, kidney disease, high cardiovascular risk groups), combining lifestyle modification (DASH diet, sodium restriction, exercise, weight loss) with drug therapy when needed. Blood lipid control aims to lower LDL cholesterol to risk-based targets (very high risk: <55mg/dL, high risk: <70mg/dL), with statins as first-line drugs. Glycemic control targets glycated hemoglobin (HbA1c) <7.0% (individually adjusted), with SGLT2 inhibitors and GLP-1 receptor agonists of proven cardiovascular benefit considered first.
For physical activity, at least 150 minutes per week of moderate aerobic exercise or 75 minutes per week of vigorous aerobic exercise is recommended. Regular exercise simultaneously improves multiple risk factors, including blood pressure, blood glucose, lipids, body weight and mental health. A Mediterranean or heart-healthy diet (centered on vegetables, fruit, whole grains and fish, minimizing saturated and trans fats) is recommended. Weight loss (maintaining BMI 20–25) and reduction of abdominal obesity (waist circumference: men <90cm, women <85cm) are also goals.
For secondary prevention, long-term use of aspirin, statins, beta-blockers and ACE inhibitors/ARBs is key. Simplified drug regimens to improve medication adherence (polypill, etc.) and regular follow-up tests are important. Because cardiac rehabilitation programs contribute to improved survival and quality of life in secondary prevention, active participation is recommended.
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407-477. DOI: 10.1093/eurheartj/ehz425. PMID: 31504439.
Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. Journal of the American College of Cardiology. 2012;60(24):e44-e164. DOI: 10.1016/j.jacc.2012.07.013. PMID: 23182125.
Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. New England Journal of Medicine. 2020;382(15):1395-1407. DOI: 10.1056/NEJMoa1915922. PMID: 32227755.
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapentaenoic acid for hypertriglyceridemia. New England Journal of Medicine. 2019;380(1):11-22. DOI: 10.1056/NEJMoa1812792. PMID: 30415628.
Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. New England Journal of Medicine. 2018;379(3):250-259. DOI: 10.1056/NEJMoa1803538. PMID: 29785878.
Khera AV, Emdin CA, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. New England Journal of Medicine. 2016;375(24):2349-2358. DOI: 10.1056/NEJMoa1605086. PMID: 27959714.
Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013;381(9867):639-650. DOI: 10.1016/S0140-6736(13)60108-7. PMID: 23439102.
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. PMID: 34458905.
Vogel B, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385-2438. DOI: 10.1016/S0140-6736(21)00684-X. PMID: 34010616.
Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal. 2013;34(38):2949-3003. DOI: 10.1093/eurheartj/eht296. PMID: 23996286.